Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database

Akahito Sako, Yoshiaki Gu, Yoshinori Masui, Kensuke Yoshimura, Hidekatsu Yanai, Norio Ohmagari
doi: https://doi.org/10.1101/2022.11.15.22281290

ABSTRACT

Background Both physicians and patients are proactive towards managing seasonal influenza in Japan and six drugs are approved. We aimed to clarify the status of anti-influenza drug use by analyzing real-world data.

Methods This retrospective study analyzed open data from the National Database of Health Insurance Claims and Specific Health Checkups, which covers most claims data from national health insurance. We estimated the annual number of patients prescribed anti-influenza drugs, their age and sex distribution, drug costs, and regional disparities for the period 2014-2020.

Results For 2014-2019, an estimated 6.7-13.4 million patients per year were prescribed anti-influenza drugs, with an annual cost of 22.3-48.0 billion JPY (Japanese Yen). In addition, 21.1-32.0 million rapid antigen tests were performed at a cost of 30.1-47.1 billion JPY. In 2017, laninamivir was the most frequently prescribed anti-influenza drug (48%), followed by oseltamivir (36%), while in 2018, the newly introduced baloxavir accounted for 40.8% of prescriptions. After the emergence of COVID-19, the number of patients prescribed anti-influenza drugs in 2020 dropped to just 14,000. In 2018, 37.6% of prescriptions were for patients aged < 20 years compared with 12.2% for those aged ≥ 65 years. Prescriptions for inpatients accounted for 1.1%, and the proportion of prescriptions for inpatients increased with age. Male were more likely than female to be prescribed anti-influenza drugs for inpatient.

Conclusions Based on our clarification of how influenza is clinically managed in Japan, future work should evaluate the clinical and economic aspects of proactively prescribing anti-influenza drugs.

BACKGROUND

Seasonal influenza is a common viral infection prevailing in winter. Although the incidence and significance of seasonal influenza has decreased since the emergence of coronavirus disease 2019 (COVID-19) (1, 2), its clinical, social, and economic impacts remain profound (3-5). In Japan, anti-influenza drugs are commonly prescribed, and both physicians and patients are proactive toward using anti-influenza drugs, even non-elderly patients without underlying disease (5-7). It has been reported that Japan consumes more anti-influenza drugs than any other country (8-11). Currently, six kinds of drugs are approved and available for seasonal influenza in Japan—amantadine, oseltamivir, zanamivir, laninamivir, peramivir, and baloxavir—even though with the exception of oseltamivir and zanamivir, there is insufficient evidence of their effectiveness. Favipiravir is also approved but limited for novel or re-emerging influenza virus infections.

The National Institute of Infectious Diseases reports data on influenza surveillance, including annual estimates of influenza cases, deaths by influenza, seasonal trends, and distribution by region and age (2). However, there is a paucity of nationwide epidemiological and economic data on the prescription of anti-influenza drugs.

In this study, we investigated the clinical epidemiology of seasonal influenza treated with anti-influenza drugs in Japan by analyzing a large open dataset from the national health insurance claims database.

METHODS

National Database Open Data (NDB Open Data)

This is a retrospective cohort study using open data from Japan’s National Database of Health Insurance Claims Information and Specified Medical Checkups (NDB). Japan has a population of 126 million and a universal health care system. The Ministry of Health, Labour and Welfare has used the NDB to collect almost all national health insurance claims for both inpatients and outpatients since 2009. The NDB contains information such as patient sex, age, diagnosis, procedures and surgeries, and the dates and doses of prescriptions issued. NDB Open Data does not provide individual data but rather aggregate data, including annual numbers of surgeries, medical services, tests, and prescriptions in Japan, stratified by sex, 5-year age intervals, inpatient/outpatient status, and geographic location of clinics or hospitals (47 prefectures) through the website (12). As of September 2022, data are available from FY2014 to FY2020. We analyzed data for this entire period with a focus on FY2018 in order to describe clinical practice before the emergence of COVID-19 and the impact of the then newly approved baloxavir. As a denominator, we used the population of Japan stratified by age, sex, and prefecture, as reported by the Statistics Bureau of Japan (13).

Several studies have examined data from the NDB (14-16) and NDB Open Data (17, 18). The need for informed consent was waived because the data published by NDB Open Data are anonymized and publicly available. The institutional review board of the National Center for Global Health and Medicine reviewed and approved the study protocol.

Anti-influenza drugs and tests for influenza

We investigated the annual prescription of five anti-influenza drugs for seasonal influenza: oseltamivir, zanamivir, laninamivir, peramivir, and baloxavir. We did not include amantadine because we consider almost all prescriptions of amantadine to be for Parkinson’s disease rather than influenza. For pediatric patients, we used the mean body weight reported for each age by the 2017 School Health Statistics and the 2010 National Growth Survey on Preschool Children. We assumed a mean body weight of 12.0 kg and 24.4 kg for boys aged 0-4 years and 5-9 years, respectively, and corresponding values of 11.5 kg and 23.9 kg for girls. Data are available on the annual prescriptions of the top 100 anti-viral drugs, including generic equivalents and dosage forms; in 2014, data are available for only the top 30 anti-viral drugs. Zanamivir has been available in Japan since 2000, oseltamivir since 2001, laninamivir and peramivir since 2010, and baloxavir since 2018. Between 2007 and 2018, oseltamivir was contraindicated for patients aged 10-19 years in Japan because some cases of neuropsychiatric adverse effects and falls were reported (7). Data on prophylactic use of anti-influenza drugs is not included in NDB Open Data because such usage is not covered by national health insurance.

We considered the following prescriptions to indicate 1 influenza patient: oseltamivir, 750 mg (capsules or dry syrup) as 1 influenza patient aged > 9 years and oseltamivir 20 mg/kg as 1 influenza patient aged ≤ 9 years; zanamivir, 20 inhalations; laninamivir, one inhalation as 1 influenza patient aged 0-9 years and two inhalations as 1 influenza patient aged > 9 years or 1 bottle of inhalation suspension; peramivir, one infusion of 300 mg or 150 mg; and baloxavir, 10 mg as 1 patient aged 0-4 years, 20 mg as 1 patient aged 5–9 years, 30 mg as 1 patient aged 10-14 years, and 40 mg as 1 patient aged >14 years.

Because NDB Open Data protects personal privacy through anonymization, there are some missing values in the data. For example, data are made available in the form of an Excel spreadsheet on the total annual prescriptions of oseltamivir 75 mg capsules and distribution by sex, 5-year age interval, and prefecture, but if the number of prescriptions in a specific cell is low, the data are masked. The cut-off values for masking are 1,000 tablets, capsules, blister packs, kits, or bottles and 1,000 g for dry syrup. For infusion bags or vials, the cut-off value was 1,000 in 2015 and has been 400 since 2016. For example, if only 450 oseltamivir capsules were prescribed for boys aged 0-4 years in 2019, this information would be masked. Moreover, even if only one cell contained a value below the cut-off, until 2017 the entire row was masked, and thereafter the cells with the two lowest values are masked. When we calculated the total number of patients prescribed anti-influenza drugs, we assumed that the prescriptions with unknown age group were adult doses.

Age distribution by sex is available, but the age distribution within each prefecture is not. When we calculated the total number of patients prescribed anti-influenza drugs in each prefecture, we extrapolated the age distribution based on that of prescriptions nationwide.

In Japan, rapid antigen tests, serologic tests, and nucleic acid amplification tests are available. These tests are performed only when ordered by a physician. Self-tests and over-the-counter retail tests are not approved in Japan. However, we calculated only rapid antigen tests, because only 14,759 serologic tests and 84 nucleic acid amplification tests were performed in 2019.

In terms of the costs associated with anti-influenza drugs and rapid antigen tests, we used only the reimbursement fees for drugs and tests and did not include the fees for physicians and pharmacists or for hospitalization. For our calculations, we assume 1 USD is equivalent 110 JPY during the study period. Accordingly, costs were calculated as follows: rapid antigen test, 1,430 JPY; one treatment course of zanamivir for adults, 34,700 JPY in 2014 and 29,420 JPY in 2019; one treatment course of oseltamivir sold under a brand name, 31,790 JPY in 2014 and 27,200 JPY in 2019, and as a generic drug, 13,600 JPY in 2019; one treatment course of laninamivir, 42,800 JPY ; single infusion of peramivir 300 mg 62,160 JPY ; and one treatment course of baloxavir, 47,890 JPY.

RESULTS

Annual number of patients and cost of anti-influenza drugs and rapid antigen tests

The annual number of patients prescribed anti-influenza drugs in 2014-2019 ranged from 6.7 to 13.4 million (Fig. 1). The annual number of rapid antigen tests performed in the same period was 21.3, 21.5, 24.6, 32.0, 24.8, and 21.1 million times, respectively. In 2017, the most prescribed anti-influenza drug was laninamivir (48.1%), followed by oseltamivir (36.2%), zanamivir (11.4%), and peramivir (4.4%). In 2018, the newly introduced baloxavir accounted for 40.8% of prescriptions, followed by oseltamivir (28.7%), laninamivir (22.9%), zanamivir (4.7%), and peramivir (2.8%). In 2019, baloxavir dropped to account for just 15.9%. After the emergence of COVID-19, the number of patients prescribed anti-influenza drugs was only 14,000 in 2020 and 1.7 million rapid antigen tests were performed.

Figure 1:
Figure 1:

Annual number of patients prescribed anti-influenza drugs in Japan (2014-2020)

The annual cost of anti-influenza drugs in 2014-2019 ranged from 22.3 to 48.0 billion JPY and that of rapid antigen tests in the same period was 31.7, 32.0, 36.1, 47.1, 35.5, and 30.1 billion JPY, respectively (Fig. 2). Until 2017, the most expensive drug was laninamivir (54.3% of the total expenditure on anti-influenza drugs in 2017), followed by oseltamivir (28.9%), zanamivir (9.7%), and peramivir (7.2%). In 2018, baloxavir accounted for 49.5%, followed by laninamivir (25.6%), oseltamivir (16.6%), peramivir (4.5%), and zanamivir (3.9%). The only generic form of an anti-influenza drug available in Japan is oseltamivir, which became available in 2018. The proportion of prescriptions for the generic forms of oseltamivir capsule and dry syrup was 36.6% and 30.0% in 2018 and 53.0% and 42.1% in 2019, respectively.

Figure 2:
Figure 2:

Annual cost of anti-influenza drugs in Japan (2014-2020)

Age and sex distribution

In 2018, the sex distribution of patients prescribed anti-influenza drugs was nearly even, with female patients accounting for 50.5% of the total (Fig. 3). Males were predominant among patients aged < 20 years, and females were predominant among patients aged ≥ 25 years. Among both sexes, most patients were aged 5-9, followed by those aged 10-14 and 0-4, with a second peak seen in those aged 35-49. Patients aged < 20 accounted for 37.6% of the total, while patients aged ≥ 65 accounted for 12.2%.

Figure 3:
Figure 3:

Age and sex distribution of patients prescribed anti-influenza drugs in 2018

With the general population as the denominator, we found the highest annual incidence of anti-influenza drug prescriptions in aged 5-9, at 259 per 1,000 population for males and 245 for females (Fig. 4). The incidence was higher for males aged 0-19 and for females aged 20-69.

Figure 4:
Figure 4:

Age and sex distribution of patients prescribed anti-influenza drugs per 1,000 population in 2018

In 2018, the most frequently prescribed drug for patients aged < 10 was oseltamivir (Fig. 5) and that for patients aged 10-94 was baloxavir. Laninamivir was the second most frequently prescribed drug for patients aged 10-59. Zanamivir was relatively frequently prescribed for patients aged 5-19, and peramivir was frequently prescribed for patients aged ≥ 75.

Figure 5:
Figure 5:

Age and anti-influenza drugs in 2018

Geographical differences by prefecture

In 2018, the number of patients prescribed anti-influenza drugs per 1,000 population was highest in Kumamoto (97.9), followed by Gifu (96.8) and Aichi (96.4) and was lowest in Okinawa (65.3), Shimane (66.4), and Aomori (66.9) (Fig. 6).

Figure 6:
Figure 6:

Geographical differences by prefecture in patients prescribed anti-influenza drugs per 1,000 population in 2018

Choice of prescription varied among the 47 prefectures (Fig. 7). Baloxavir was the most frequently prescribed drug in 39 prefectures, the second most in 6 prefectures, and the third most in 2 prefectures. Baloxavir accounted for the highest proportion in Aichi (50.7%) and the lowest in Okinawa (26.1%). Oseltamivir was the most frequently prescribed drug in 6 prefectures, the second most in 38 prefectures, and the third most in 3 prefectures. Oseltamivir accounted for the highest proportion in Okinawa (40.4%) and the lowest in Gifu (22.1%). Laninamivir was the most frequently prescribed drug in 2 prefectures, the second most in 3 prefectures, and the third most in 42 prefectures. Laninamivir accounted for the highest proportion in Shimane (35.1%) and the lowest in Mie (15.2%). Zanamivir was the least frequently prescribed drug in 9 prefectures and accounted for the highest proportion in Yamanashi (8.7%) and the lowest in Shiga (2.1%). Peramivir was the least frequently prescribed drug in 38 prefectures and accounted for the highest proportion in Iwate (6.5%) and the lowest in Saga (0.7%).

Figure 7:
Figure 7:

Geographical differences by prefecture in prescriptions in 2018

Inpatient and outpatient prescriptions

Prescriptions for inpatients accounted for 1.1% of the total (Fig. 8). The proportion of prescriptions for inpatients increased with age. Male were more likely to be prescribed anti-influenza drugs for inpatient, regardless of age. The most frequently prescribed drug for inpatients was peramivir (61.8%), followed by oseltamivir (28.2%), baloxavir (7.1%), and laninamivir (3.0%). Peramivir was the most frequently prescribed drug among male inpatients aged < 15 and ≥ 65 years; data for 15-29 year olds were not available due to the small number of inpatients (Fig. 9). Peramivir was the most frequently prescribed drug among female inpatients aged < 10 and ≥ 65 years; data for 10-24 year olds were not available due to the small number of inpatients (Fig. 10). Peramivir for inpatients accounted for 25.1% of all peramivir prescriptions.

Figure 8:
Figure 8:

Proportion of inpatients by age and sex in 2018

Figure 9:
Figure 9:

Inpatient prescriptions for males in 2018

Figure 10:
Figure 10:

Inpatient prescriptions for females in 2018

The proportion of inpatient prescriptions varied among prefectures. Hokkaido had the highest proportion (2.1%), followed by Iwate (1.6%) and Toyama (1.5%). Yamanashi and Wakayama had the lowest proportion (0.2% each). In Shimane and Tottori, inpatient prescription data were not available due to the small number of inpatients. Peramivir was the most frequently prescribed anti-influenza drug for inpatients in Gifu (81.6%) and the least frequently prescribed in Okinawa (47.9%) (Fig. 11).

Figure 11:
Figure 11:

Regional differences in inpatient prescriptions in 2018

DISCUSSION

This nationwide retrospective study investigated annual trends in anti-influenza drug use in Japan over the six-year period of 2014-2020. The estimated annual number of patients prescribed these drugs ranged from 6.7 to 13.4 million, while the costs ranged from JPY 30.1 to 47.1 billion. Patients aged < 20 years accounted for 46.1% of the anti-influenza prescriptions. The most frequently prescribed drug until 2017 was laninamivir, which was overtaken by the newly approved baloxavir in 2018, before prescriptions for baloxavir decreased dramatically the following year.

In Japan, the National Epidemiological Surveillance for Infectious Diseases (NESID) program is implemented nationwide (10, 19). NESID is based on reports from about 5,000 sentinel hospitals and clinics, accounting for about one-tenth of the pediatric and internal medicine facilities nationwide. The number of influenza patients estimated by NESID from the 2014-15 flu season to the 2019-20 flu season was 9.4, 9.8, 10.3, 14.4, 11.7, and 7.3 million, respectively, dropping to just 14,000 in the 2020–21 flu season. Starting with the 2018-19 flu season, the estimation method was changed because the previous method resulted in overestimation (about 1.54 times) and the data prior to the 2017-18 season were corrected retrospectively. Our estimation of the annual number of patients prescribed anti-influenza drugs is similar to the number of influenza patients reported by NESID. This indicates that most influenza patients in Japan received an anti-influenza prescription. In addition to our study, several other studies have investigated influenza by examining administrative claims databases, such as the Diagnosis Procedure Combination database (20, 21), the Japan Medical Data Center database (22-24), and the NDB (25). These databases are useful because they complement public health surveillance data, which sometimes lack clinical information such as prescriptions. Secondary analyses of claims databases are less susceptible to underestimations and require less effort and cost compared with hospital- and physician-based surveillance.

It has been said that the management of influenza in Japan is unique, but analysis of large datasets has been lacking. Among studies conducted in Japan to date, an online survey of 200 households in Japan conducted in 2019 showed that 76% of participants with influenza-like illness visited a healthcare facility, 89% underwent a rapid influenza diagnostic test, and 95% who tested positive were treated with antivirals (5). A study at a university hospital in France investigated 755 confirmed cases of influenza between 2018 and 2019, a quarter of which required hospitalization (26). Oseltamivir was prescribed in 59.9% of cases, a rate the authors considered low and in need of improvement. A single-center study in Japan reported that prescription of anti-influenza drugs was associated with a positive influenza rapid antigen test, physician experience, and high regional influenza activity, whereas patient age and comorbidities were not associated (9). The authors suggested the need for educational intervention because the evidence-based prescription of anti-influenza drugs was often neglected in clinical practice in Japan. Our nationwide data support the findings and concerns raised by these previous Japanese studies.

Evidence for oseltamivir and zanamivir related to hard endpoints such as hospitalization and death had been questioned because systematic reviews showed the efficacy of only soft endpoints such as time to alleviation (27-29). However, in 2015, a systematic review of oseltamivir prescribed for patients with documented influenza infection showed that oseltamivir was efficacious for reducing lower respiratory tract infections and hospital admissions (30). Recent US guidelines (31) are more proactive than before (32) in terms of prescribing anti-influenza drugs, not only for elderly and high-risk patients but also for otherwise healthy patients. In Japan, physicians seem to have routinely and proactively prescribed anti-influenza drugs regardless of the accumulation of evidence and updates to guidelines. Oseltamivir and zanamivir are the main anti-influenza drugs prescribed in the US and Europe (11, 31). Our analysis showed that laninamivir has been frequently prescribed in Japan, but evidence of its effectiveness is limited. Phase II trials in 12 countries failed to show that it was more efficacious compared with placebo (33). A randomized controlled trial in Japan showed non-inferiority to oseltamivir in terms of time to illness alleviation, and laninamivir has been approved only in Japan (34, 35). The emergence of variants with less susceptibility to baloxavir was reported in the first randomized controlled trial (36). The Japan Pediatric Society did not recommend baloxavir for patients aged < 12 years because of concern about the lack of evidence for children as well as the emergence of variants in 2018. The Japanese Association for Infectious Diseases (37) described the characteristics of baloxavir but did not issue a position statement in 2018 (38). Despite these concerns, baloxavir was the most prescribed anti-influenza drug in the 2018-19 flu season, just after it was released. In 2019, the Japanese Association for Infectious Diseases announced that they could not make a recommendation for adults because of a lack of evidence. In the 2019-20 flu season, prescriptions of baloxavir dropped sharply. Although we could not determine why laninamivir and baloxavir are prescribed so frequently, Japanese physicians and patients might prefer the simplicity of single administration. It also seems that physicians prefer new drugs to conventional drugs and that prescriptions were not driven by evidence or guidelines but rather by the promotion of new drugs by pharmaceutical companies (39, 40). Therefore, future studies should investigate how Japanese physicians decide which drugs to prescribe for influenza.

Our data showed a higher incidence of influenza in children. A quarter of the general population of children aged 5-9 years are prescribed anti-influenza drugs each year. There is a second peak in people in their 30s and 40s, with a higher incidence in women. This second peak may reflect the fact that some of these patients are childcare workers or the parents of children with influenza. In Japan, mothers spend much more time engaged in household and childcare work than fathers, according to a national survey on time use and leisure activities, and most nursery school and kindergarten teachers in Japan are women. A previous study that analyzed data from city-wide primary school seasonal influenza surveillance and a household survey showed that estimated contact intensity was higher in mother–child pairs than in father–child pairs (41). It also showed that older patients, especially older males, were more likely to be hospitalized for influenza or to be infected with influenza during hospitalization. The in-hospital prescription rate for females in their 70s, 80s, and 90s was 3.6%, 11.4%, and 16.8%, respectively, and while it was higher for their male counterparts at 6.7%, 16.0%, and 22.3%. Boys were more likely to be prescribed anti-influenza drugs and their in-hospital prescription rate was higher than that for girls. It has been reported that males are more vulnerable to influenza in terms of risk of hospitalization and mortality compared with females (42). In Hong Kong, male patients, especially those aged < 18 years, tended to have a higher excess hospitalization rate compared with female patients (33). A retrospective single-center study in Canada that investigated the risk of hospitalization due to influenza in childhood showed that male sex was associated with a higher risk of hospitalization (adjusted odds ratio: 1.9; 95% confidence interval: 1.0-3.7)(43). Our data are compatible with those of these previous studies, suggesting the need to take the patient’s sex into consideration in the management of influenza.

Differences in the incidence of influenza by prefecture have been reported previously by NESID (19). The present study is the first to show a geographical disparity in the choice of anti-influenza drugs prescribed. Previous studies of data from NDB Open Data have shown regional disparities in clinical practice in terms of surgery for nephrectomy and nephroureterectomy (44) as well as prescriptions for chronic kidney disease (45). In addition to variance in the aging population and disease prevalence, the maldistribution of specialists might explain these disparities. However, influenza is a very common disease and most patients were treated by a pediatrician, internist, or general practitioner rather than an infectious disease or respiratory disease specialist. Establishment and dissemination of clinical guidelines is one of the most important factors in reducing disparities and standardizing clinical practice (46, 47). The Japan Pediatric Society has published clinical guidelines and recommendations about the choice of anti-influenza drugs, but there are no comprehensive clinical guidelines for seasonal influenza in adult patients, such as those published by the Infectious Diseases Society of America (31), and the Japanese Association for Infectious Diseases does not determine the grade of recommendation based on clinical evidence (37). It is therefore necessary to investigate how aware physicians are about the current guidelines and evidence for the effectiveness of anti-influenza drugs.

After the emergence of COVID-19, prescriptions for anti-influenza drugs decreased in 2019 and then dropped dramatically to just 14,000 in 2020. Although the significance of influenza was decreased, influenza is expected to re-emerge after restrictions to limit the spread of COVID-19 are lifted. Diagnosing COVID-19 depends largely on rapid antigen or polymerase chain reaction tests of nasopharyngeal swabs or saliva samples. Oral medications for COVID-19 such as molnupiravir and nirmatrelvir-ritonavir have recently become available. The impact of COVID-19 has decreased because of widespread vaccination, the emergence of less severe strains such as the Omicron variant, and the development of pharmacotherapies. Based on the similarity between influenza and COVID-19, we need to learn from both the strengths and shortcomings of influenza management in Japan in terms of clinical practice, logistics, and health policy.

This study has several limitations. First, NDB Open Data does not contain individual data but rather is aggregate data. The number of patients prescribed anti-influenza drugs can only be estimated, and the actual doses for pediatric patients and multiple prescriptions for individuals are not known. Second, patient characteristics other than age, sex, prefecture, inpatient/outpatient status, and outcome data are not available. Even if a patient’s condition worsens and they are hospitalized the day after being prescribed anti-influenza drugs at an outpatient clinic, NDB Open Data only records that they were prescribed anti-influenza drugs as an outpatient. Third, as mentioned in the Methods section, the dataset contained missing values. However, these missing values accounted for only 0.2% of prescriptions, and the reason for the masked data is because of the small number of prescriptions in specific age categories and prefectures. Therefore, the influence of missing values is considered to be small. Fourth, there is a delay in data availability. NDB Open Data published the data for FY2020 in September 2022. Although these data are useful for public health surveillance, the delay in their publication makes it impossible to utilize them for timely management of seasonal influenza. Fifth, under the national health insurance scheme in Japan, reimbursements are made for anti-influenza drugs only when prescribed for treatment, not for prevention, and thus NDB contains only data on prescriptions for treatment. However, it cannot be ruled out that some prescriptions for prevention were included in the dataset and this may have resulted in overestimation of the number of patients.

Despite these limitations, our study clarifies the clinical epidemiology of seasonal influenza treated with anti-influenza drugs in Japan, where both physicians and patients are proactive toward management with anti-influenza drugs and rapid antigen tests. These findings from nationwide real-world data can be utilized for public health management, health policy, and clinical practice not only in relation to influenza but also to COVID-19 and other emerging infectious diseases. Access to physicians, rapid antigen tests, and anti-influenza drugs are strengths of the Japanese health care system, but the choice of which anti-influenza drug to prescribe remains unclear based on the clinical evidence currently available. Further research is needed to elucidate how physicians choose which anti-influenza drugs to prescribe.

Data Availability

The datasets used and/or analyzed during the current study are publicly available.

Declarations

Ethics approval and consent to participate

The requirement for informed consent was waived because this was a retrospective study of publicly available, anonymized administrative data. The study was approved by the Institutional Review Board of the National Center for Global Health and Medicine (NCGM-S-003424).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed in this study are publicly available.

Competing interests

The authors have no conflicts of interest to disclose.

Funding

This work was supported by a grant from the National Center for Global Health and Medicine (Grant Numbers: 19A1026 and 20A3001). The funding institutions had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication.

Authors’ contributions

AS is the guarantor of this work, had full access to all data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version of the manuscript.

Study concept and design: AS

Acquisition, analysis, or interpretation of data: AS, YG, NO

Drafting of the manuscript: AS

Critical revision of the manuscript for important intellectual content: AS, YM, KY, HY, YG, NO

Administrative, technical, or material support: HY

Study supervision: HY, YG, NO

Acknowledgements

Not applicable

Abbreviations

NDB
National Database of Health Insurance Claims and Specific Health Checkups
COVID-19
Coronavirus disease 2019
NESID
National Epidemiological Surveillance for Infectious Diseases
JPY
Japanese Yen

REFERENCES

  1. 1.↵
    Sawakami T, Karako K, Song P. Behavioral changes adopted to constrain COVID-19 in Japan: What are the implications for seasonal influenza prevention and control? Glob Health Med. 2021;3(3):125–8.
    OpenUrl
  2. 2.↵
    Hibiya K, Iwata H, Kinjo T, Shinzato A, Tateyama M, Ueda S, et al. Incidence of common infectious diseases in Japan during the COVID-19 pandemic. PLoS One. 2022;17(1):e0261332.
    OpenUrl
  3. 3.↵
    Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421.
    OpenUrl
  4. 4.
    Taniguchi K, Ikeda S, Hagiwara Y, Tsuzuki D, Klai M, Sakai Y, et al. Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta-analysis. Influenza Other Respir Viruses. 2021;15(2):293–314.
    OpenUrl
  5. 5.↵
    Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness management in Japan. BMC Public Health. 2020;20(1):568.
    OpenUrl
  6. 6.
    WHO public health research agenda for influenza: 2017 update. World Health Organization. 2017.
  7. 7.↵
    Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother. 2011;17(5):595–601.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Chong Y, Matsumoto S, Kang D, Ikematsu H. Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan. Influenza Other Respir Viruses. 2019;13(2):115–22.
    OpenUrl
  9. 9.↵
    Nakajima K, Akebo H, Tsugihashi Y, Ishimaru H, Sada R. Association of physician experience with a higher prescription rate of anti-influenza agents in low-risk patients. Intern Emerg Med. 2021;16(5):1215–21.
    OpenUrl
  10. 10.↵
    Zaraket H, Saito R. Japanese Surveillance Systems and Treatment for Influenza. Curr Treat Options Infect Dis. 2016;8(4):311–28.
    OpenUrl
  11. 11.↵
    Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza – review of recent systematic reviews and meta-analyses European Centre for Disease Prevention and Control. 2017.
  12. 12.↵
    Ministry of Health LaW. NDB OpenData 2022 [Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html.
  13. 13.↵
    Japan SBo. Portal Site of Official Statistics of Japan 2022 [Available from: https://www.e-stat.go.jp/.
  14. 14.↵
    Okumura Y, Usami M, Okada T, Saito T, Negoro H, Tsujii N, et al. Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy. J Child Adolesc Psychopharmacol. 2018;28(7):454–62.
    OpenUrl
  15. 15.
    Sugiyama T, Imai K, Ihana-Sugiyama N, Tanaka H, Yanagisawa-Sugita A, Sasako T, et al. Variation in process quality measures of diabetes care by region and institution in Japan during 2015-2016: An observational study of nationwide claims data. Diabetes Res Clin Pract. 2019;155:107750.
    OpenUrlPubMed
  16. 16.↵
    Hirose N, Ishimaru M, Morita K, Yasunaga H. A review of studies using the Japanese National Database of Health Insurance Claims and Specific Health Checkups. Annals of Clinical Epidemiology. 2020;2(1):13–26.
    OpenUrl
  17. 17.↵
    Nakanishi T, Inose R, Kusama Y, Ishikane M, Kajihara T, Yahara K, et al. The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017. Jpn J Infect Dis. 2022;75(2):177–82.
    OpenUrl
  18. 18.↵
    Yoshimura K, Hashimoto T, Sato Y, Sato A, Takeuchi T, Watanabe H, et al. Survey of Anticonvulsant Drugs and Lithium Prescription in Women of Childbearing age in Japan Using a Public National Insurance Claims Database. Clinical Neuropsychopharmacology and Therapeutics. 2018;9:20–8.
    OpenUrl
  19. 19.↵
    Ohkusa Y, Sugawara T, Takahashi K, Kamei M. Comparative study of preciseness in the regional variation of influenza in Japan among the National Official Sentinel Surveillance of Infectious Diseases and the National Database of Electronic Medical Claims. Biosci Trends. 2018;12(6):636–40.
    OpenUrl
  20. 20.↵
    Uda K, Okubo Y, Shoji K, Miyairi I, Morisaki N, Michihata N, et al. Trends of neuraminidase inhibitors use in children with influenza related respiratory infections. Pediatr Pulmonol. 2018;53(6):802–8.
    OpenUrl
  21. 21.↵
    Takeuchi M, Yasunaga H, Horiguchi H, Matsuda S. Clinical Features of Infants Hospitalized for 2009 Pandemic Influenza A (H1N1) in Japan: Analysis Using a National Hospital Discharge Database. Pediatr Infect Dis J. 2012;31(4):368–72.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Takeuchi M, Kawakami K. Association of baloxavir marboxil prescription with subsequent medical resource utilization among school-aged children with influenza. Pharmacoepidemiol Drug Saf. 2021;30(6):779–86.
    OpenUrl
  23. 23.
    Yamana H, Ono S, Michihata N, Jo T, Yasunaga H. Association between Maoto Use and Hospitalization for Seasonal Influenza in a Nonelderly Cohort in Japan. Intern Med. 2021;60(21):3401–8.
    OpenUrl
  24. 24.↵
    Ono S, Ono Y, Matsui H, Yasunaga H. Factors associated with hospitalization for seasonal influenza in a Japanese nonelderly cohort. BMC Public Health. 2016;16:922.
    OpenUrl
  25. 25.↵
    Nakamura Y, Sugawara T, Kawanohara H, Ohkusa Y, Kamei M, Oishi K. Evaluation of estimated number of influenza patients from national sentinel surveillance using the national database of electronic medical claims. Jpn J Infect Dis. 2015;68(1):27–9.
    OpenUrl
  26. 26.↵
    Cizeron A, Saunier F, Gagneux-Brunon A, Pillet S, Cantais A, Botelho-Nevers E. Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season. J Antimicrob Chemother. 2021;76(4):1057–62.
    OpenUrl
  27. 27.↵
    Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;2014(4):Cd008965.
    OpenUrl
  28. 28.
    Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729–37.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019;68(6):e1–e47.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003–32.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    Wang XL, Yang L, Chan KH, Chan KP, Cao PH, Lau EH, et al. Age and Sex Differences in Rates of Influenza-Associated Hospitalizations in Hong Kong. Am J Epidemiol. 2015;182(4):335–44.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Watanabe A. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother. 2013;19(1):89–97.
    OpenUrlCrossRefPubMed
  35. 35.↵
    Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, Group MS. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167–75.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018;379(10):913–23.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, et al. JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG. J Infect Chemother. 2016;22(7 Suppl):S1–S65.
    OpenUrl
  38. 38.↵
    Cap-dependent endonuclease inhibitor Baloxavir marboxil (Xofluza®)|The Japanese Association for Infectious Diseases 2022 [Available from: https://www.kansensho.or.jp/modules/en/index.php?content_id=2.
  39. 39.↵
    Saito S, Mukohara K, Bito S. Japanese practicing physicians’ relationships with pharmaceutical representatives: a national survey. PLoS One. 2010;5(8):e12193.
    OpenUrlCrossRefPubMed
  40. 40.↵
    Pegler S, Underhill J. Evaluating the safety and effectiveness of new drugs. Am Fam Physician. 2010;82(1):53–7.
    OpenUrlPubMedWeb of Science
  41. 41.↵
    Endo A, Uchida M, Kucharski AJ, Funk S. Fine-scale family structure shapes influenza transmission risk in households: Insights from primary schools in Matsumoto city, 2014/15. PLoS Comput Biol. 2019;15(12):e1007589.
    OpenUrlCrossRef
  42. 42.↵
    Sue K. The science behind “man flu”. BMJ. 2017;359:j5560.
    OpenUrlFREE Full Text
  43. 43.↵
    Quach C, Piche-Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics. 2003;112(3 Pt 1):e197–201.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    Sugihara T, Yasunaga H, Matsui H, Kamei J, Fujimura T, Kume H. Regional clinical practice variation in urology: Usage example of the Open Data of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Urol. 2019;26(2):303–5.
    OpenUrlPubMed
  45. 45.↵
    Inoue R, Nishi H, Tanaka T, Nangaku M. Regional variance in patterns of prescriptions for chronic kidney disease in Japan. Clin Exp Nephrol. 2019;23(6):859–64.
    OpenUrl
  46. 46.↵
    Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Nobel TB, Lavery JA, Barbetta A, Gennarelli RL, Lidor AO, Jones DR, et al. National guidelines may reduce socioeconomic disparities in treatment selection for esophageal cancer. Dis Esophagus. 2019;32(5).
Back to top
Posted November 17, 2022.
Download PDF
Data/Code
Email
Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database
Akahito Sako, Yoshiaki Gu, Yoshinori Masui, Kensuke Yoshimura, Hidekatsu Yanai, Norio Ohmagari
medRxiv 2022.11.15.22281290; doi: https://doi.org/10.1101/2022.11.15.22281290
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area